Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. SAB Herbals and Nutraceuticals
483
•SAB Herbals and Nutraceuticals•November 22, 2024

SAB Herbals and Nutraceuticals – FDA 483, Nov 22, 2024

Record Details

During an inspection conducted by the U.S. Food and Drug Administration (FDA) from November 18-22, 2024, at SAB Herbals and Nutraceuticals in Udham Singh Nagar, India, several significant observations were noted, detailed in a Form FDA 483. This document highlights potential deviations from current Good Manufacturing Practices (cGMP) for drug product manufacturing. The primary issues revolved around inadequate laboratory controls and quality assurance processes. Specifically, the firm was cited for not establishing scientifically sound specifications and test procedures for components and in-process materials. For example, an impurity profile assessment was absent for a key raw material used in multiple manufacturing cycles. Additionally, the company failed to perform essential growth promotion tests on in-house culture media prior to using them for microbial testing of finished API products, which is crucial for ensuring test validity. Furthermore, the inspection revealed that the responsibilities and procedures for the quality control unit, particularly concerning growth promotion testing, were not formally documented in writing. There was also a failure to conduct specific identification and assay tests on incoming batches of critical components, such as a bulk material used in API production, relying instead solely on supplier reports. These observations indicate a need for SAB Herbals and Nutraceuticals to implement robust corrective actions. The firm is expected to address these deficiencies to ensure compliance with cGMP regulations, thereby safeguarding the identity, strength, quality, and purity of its drug products.

Company
SAB Herbals and Nutraceuticals
Inspection date
November 22, 2024
Product type
drugs
Office
Office of Inspections and Investigations
People
  • Awadhesh Kumar Singh (Head of Technical Compliance and Partner)
  • Truong X. Nguyen (Investigator)
View Company Profile

ID · 5d021885-f518-4a1d-bbbb-42a03e47b716

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore SAB Herbals and Nutraceuticals
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.